Results 81 to 90 of about 548,525 (315)
Case Reports in Hematology, 2019 Brentuximab vedotin (BV), an antibody drug conjugate against CD30, has been increasingly used in clinical practice, and the less common adverse events associated to the drug are not well described.
Aliana Meneses Ferreira +3 more
doaj +1 more source
Orphanet Journal of Rare Diseases, 2017 Background Autosomal recessive bleeding disorders (ARBDs) include deficiencies of clotting factors I, II, V, VII, X, XI, XIII, vitamin K dependent clotting factors, combined factor V & VIII, Von Willebrand Disease (vWD) type 3, Glanzmann’s thrombasthenia
Arshi Naz +9 more
doaj +1 more source
Aging and Cancer, EarlyView.This study aimed to evaluate the prognostic value of ELN2017 in predicting survival outcomes and to assess the impact of clinical and molecular factors such as age, FLT3 and NPM1 mutations, and allogeneic hematopoietic stem cell transplantation (allo‐HSCT).
Mobina Shrestha +4 more
wiley +1 more source
METHOTREXATE-ASSOCIATED STEVENS-JOHNSON SYNDROME AND TOXIC EPIDERMAL NECROLYSIS: TWO CASE REPORTS
Hematology, Transfusion and Cell TherapyObjective: Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) are rare but severe mucocutaneous diseases. These conditions are mostly drug-induced and have high mortality rates.
Yakup Unsal +5 more
doaj +1 more source
Bacterial genomics reveal the complex epidemiology of an emerging pathogen in Arctic and boreal ungulates [PDF]
, 2016 Northern ecosystems are currently experiencing unprecedented ecological change, largely driven by a rapidly changing climate. Pathogen range expansion, and emergence and altered patterns of infectious disease, are increasingly reported in wildlife at ...
Amanda Niptanatiak +18 more
core +2 more sources
Bone Marrow Transplantation in Immunodeficiency Diseases
Annals of Medicine, 1996 Bone marrow transplantation (BMT) has become the treatment of choice in an increasing number of primary immunodeficiency disorders. In many of these otherwise lethal genetic diseases, BMT can completely reverse the immunological abnormality and patients may be permanently cured.
openaire +2 more sources
Aging Is a Key Driver for Adult Acute Myeloid Leukemia
Aging and Cancer, EarlyView.Acute myeloid leukemia (AML) is a classical age‐related hematologic malignancy, and a key driver of AML is aging, which profoundly regulates intrinsic factors such as genomic instability, epigenetic reprogramming, and metabolic dysregulation, and alters bone marrow microenvironment.
Rong Yin, Haojian Zhang
wiley +1 more source
Mutant NPM1 in Acute Myeloid Leukemia Initiation and Maintenance
Aging and Cancer, EarlyView.NPM1 mutations drive acute myeloid leukemia by acting as neomorphic transcriptional regulators that cooperate with Menin–MLL and XPO1 to sustain HOX/MEIS1 expression and block differentiation. Targeting these mutant‐specific transcriptional dependencies provides a rational therapeutic strategy for NPM1‐mutated AML.
Yanan Jiang +3 more
wiley +1 more source
Journal of Hematology & Oncology, 2016 Background The efficient generation of hematopoietic stem cells (HSCs) from human-induced pluripotent stem cells (iPSCs) holds great promise in personalized transplantation therapies.
Yulin Xu +18 more
doaj +1 more source